Arbutus Biopharma (ABUS) Times Interest Earned (2017 - 2026)

Arbutus Biopharma has disclosed Times Interest Earned across 10 years of filings, most recently posting $9935.8 for Q1 2026.

• Times Interest Earned for Q1 2026 came in at $9935.8, up 1182.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $1819.2 (up 366.31% YoY), and the FY2025 annual result was -$393.4, up 29.38% from the prior year.
• Times Interest Earned came in at $9935.8 for Q1 2026 at Arbutus Biopharma, up from -$293.89 in the prior quarter.
• In the past five years, Times Interest Earned ranged from a high of $9935.8 in Q1 2026 to a low of -$917.82 in Q1 2025.
• The 5-year median for Times Interest Earned is -$293.89 (2025), against an average of $283.59.
• Across the five-year window, Times Interest Earned sank 1028.81% in 2023 and surged 1182.54% in 2026, its largest moves.
• Arbutus Biopharma's Times Interest Earned stood at -$73.02 in 2022, then sank by 545.78% to -$471.52 in 2023, then grew by 1.5% to -$464.43 in 2024, then soared by 36.72% to -$293.89 in 2025, then surged by 3480.79% to $9935.8 in 2026.
• The last three Times Interest Earned figures came in at $9935.8 (Q1 2026), -$293.89 (Q4 2025), and -$376.48 (Q3 2025), per Business Quant data.